Fujita Wakako
Department of Medical Pharmacology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Front Cell Neurosci. 2020 Nov 13;14:609362. doi: 10.3389/fncel.2020.609362. eCollection 2020.
Heteromers between mu opioid receptor (MOPr) and delta opioid receptor (DOPr) (i.e., MOPr-DOPr heteromer) have been found to be expressed in different brain regions, in the spinal cord, and in dorsal root ganglia. Recent studies on this heteromer reveal its important pathophysiological function in pain regulation including neuropathic pain; this suggests a role as a novel therapeutic target in chronic pain management. In addition, receptor transporter protein 4 (RTP4) has been shown to be involved in the intracellular maturation of the MOPr-DOPr heteromers. RTP4 appears to have unique distribution being highly expressed in sensory neurons and also macrophages; the latter are effector cells of the innate immune system that phagocytose foreign substances and secrete both pro-inflammatory and antimicrobial mediators; this suggests a possible contribution of RTP4 to neuronal immune-related pathological conditions such as neuropathic pain. Although RTP4 could be considered as an important therapeutic target in the management of pain via MOPr-DOPr heteromer, a few reports have supported this. This review will summarize the possible role or functions of the MOPr-DOPr heteromer and its regulatory molecule RTP4 in pain modulation at sensory neurons.
已发现μ阿片受体(MOPr)与δ阿片受体(DOPr)之间的异聚体(即MOPr-DOPr异聚体)在不同脑区、脊髓和背根神经节中表达。最近对该异聚体的研究揭示了其在疼痛调节(包括神经性疼痛)中的重要病理生理功能;这表明其在慢性疼痛管理中作为新型治疗靶点的作用。此外,已证明受体转运蛋白4(RTP4)参与MOPr-DOPr异聚体的细胞内成熟过程。RTP4似乎具有独特的分布,在感觉神经元以及巨噬细胞中高表达;后者是先天性免疫系统的效应细胞,可吞噬外来物质并分泌促炎和抗菌介质;这表明RTP4可能与诸如神经性疼痛等神经元免疫相关病理状况有关。尽管RTP4可被视为通过MOPr-DOPr异聚体进行疼痛管理的重要治疗靶点,但只有少数报告支持这一点。本综述将总结MOPr-DOPr异聚体及其调节分子RTP4在感觉神经元疼痛调节中的可能作用或功能。